Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05613842 | Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)(BOP) | completed | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01607879 | Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation | completed | Phase 2 | 48 | Medical College of WisconsinOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05516329 | Study of 18F-Thretide PET/CT in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT01558427 | Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer | completed | Phase 2 | 62 | University Hospital, GhentOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT04614363 | 68 Ga-PSMA for High Risk Prostate Cancer | completed | Phase 1 / Phase 2 | 80 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT00668642 | Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer | completed | Phase 2 | 20 | Endeavor HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT01331083 | A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 68 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT00002889 | Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer | completed | Phase 2 | 180 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT00093457 | Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer | completed | Phase 2 | 28 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00258388 | Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 82 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 4, 2023 | clinicaltrials |
| NCT01075308 | SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer | completed | Phase 2 | 32 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01619813 | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 85 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04936334 | The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer | completed | Phase 2 | 51 | Clinton BahlerOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT01666808 | FACBC Outcomes for Post Prostatectomy | completed | Phase 2 / Phase 3 | 165 | Emory UniversityOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 66 | University of Wisconsin, MadisonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03658447 | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)(PRINCE) | completed | Phase 1 / Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT02326805 | PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05549778 | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC(PEACe) | completed | Phase 1 / Phase 2 | 12 | Jiangnan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00003871 | PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 60 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00005847 | Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003614 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT04676607 | SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT00866554 | Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy | completed | Phase 2 | 60 | CHU de Quebec-Universite LavalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT00987753 | Study Evaluating the Safety and Tolerability of L-377202 | completed | Phase 1 / Phase 2 | 13 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT00583752 | Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21(APP21) | completed | Phase 2 | 50 | David M LubaroffOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT02058706 | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | completed | Phase 2 | 71 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT01278914 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Oslo University HospitalOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT03429244 | PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer | completed | Phase 2 | 36 | Indiana UniversityOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT00114985 | Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT03406858 | Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT01751438 | Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) | completed | Phase 2 | 180 | M.D. Anderson Cancer CenterOTHER | 2 | Apr 27, 2023 | clinicaltrials |
| NCT02159950 | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT02624518 | 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 122 | Andrei IagaruOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05806853 | PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study | completed | Phase 2 | 60 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT02278055 | Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03679260 | Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance | completed | Phase 2 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03103152 | A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression(PROVENT) | completed | Phase 2 / Phase 3 | 104 | Queen Mary University of LondonOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04179968 | The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer | completed | Phase 2 | 20 | Dana MathewsOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT01385059 | Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer | completed | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT03043807 | A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04627896 | Targeted Microwave Focal Therapy | completed | Phase 2 / Phase 3 | 11 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT01903408 | Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment(PLATIN) | completed | Phase 2 | 199 | Heidelberg UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT02311049 | Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01921803 | Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer(Hypofraction) | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT00547339 | Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 94 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 26, 2023source: clinicaltrials